Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis

Weckbecker, 2003, Opportunities in somatostatin research: biological, chemical and therapeutic aspects, Nat Rev Drug Discovery, 2, 999, 10.1038/nrd1255

Csaba, 2012, Molecular mechanisms of somatostatin receptor trafficking, J Mol Endocrinol, 48, R1, 10.1530/JME-11-0121

Schmid, 2008, Pasireotide (SOM230): Development, mechanism of action and potential applications, Mol Cell Endocrinol, 286, 69, 10.1016/j.mce.2007.09.006

Contour-Galcéra, 2005, 3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists, Bioorg Med Chem Lett, 15, 3555, 10.1016/j.bmcl.2005.05.061

Wolkenberg, 2008, Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors, Curr Opin Drug Discov Devel, 11, 446

Wolkenberg, 2011, Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2, J Med Chem, 54, 2351, 10.1021/jm101501b

Ishida, 2020, Discovery and SAR Studies of orally active somatostatin receptor subtype-2 (SSTR2) agonists for the treatment of acromegaly, ACS Chem Neurosci, 11, 1482, 10.1021/acschemneuro.0c00124

Walker, 1999, Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affnity for open and inactivated states, Br J Pharmacol, 128, 444, 10.1038/sj.bjp.0702774

Witchel, 2000, Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current, Clin Exp Pharmacol Physiol, 27, 753, 10.1046/j.1440-1681.2000.03337.x

Lagrutta, 2008, The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview Curr, Top Med Chem, 8, 1102, 10.2174/156802608785700016

Ekins, 2002, Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-Go-Go-related gene potassium channel, J Pharmacol Exp Ther, 301, 427, 10.1124/jpet.301.2.427

Farid, 2006, New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies, Bioorg Med Chem, 14, 3160, 10.1016/j.bmc.2005.12.032

Thai, 2007, Predictive Models for hERG Channel Blockers: Ligand-Based and Structure-Based Approaches, Curr Med Chem, 14, 3003, 10.2174/092986707782794087

Aronov, 2008, Ligand structural aspects of hERG channel blockade, Curr Top Med Chem, 8, 1113, 10.2174/156802608785700061

Du-Cuny, 2011, Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Chananel Blocker Modeling, J Chem Inf Model, 51, 2948, 10.1021/ci200271d

Jamieson, 2006, Medicinal Chemistry of hERG Optimizations: Highlights and Hang-ups, J Med Chem, 49, 5029, 10.1021/jm060379l

Waring, 2007, A quantitative assessment of hERG liability as a function of lipophilicity, Bioorg Med Chem Lett, 17, 1759, 10.1016/j.bmcl.2006.12.061

Arnott, 2012, The influence of lipophilicity in drug discovery and design, Expert Opin Drug Discov, 7, 863, 10.1517/17460441.2012.714363

Reasor, 1989, A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs, Toxicol Appl Pharmacol, 97, 47, 10.1016/0041-008X(89)90054-9

Halliwell, 1997, Cationic amphiphilic drug-induced phospholipidosis, Toxicol Pharmacol, 25, 53

Vitovič, 2008, Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis, J Med Chem, 51, 1842, 10.1021/jm7013953

Ploemen, 2004, Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potentialA case study with structurally related piperazines, Exp Toxicol Pathol, 55, 347

Ratcliffe, 2009, Medicinal chemistry strategies to minimize phospholipidosis, Curr Med Chem, 16, 2816, 10.2174/092986709788803213

Fischer, 2012, In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets, J Med Chem, 55, 126, 10.1021/jm201082a

Charifson, 2014, Acidic and basic drugs in medicinal chemistry: a perspective, J Med Chem, 57, 9701, 10.1021/jm501000a

Guram, 2007, New Catalysts for Suzuki−Miyaura Coupling Reactions of Heteroatom-Substituted Heteroaryl Chlorides, J Org Chem, 72, 5104, 10.1021/jo070341w

Lilienkampf, 2009, Structure−Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis, J Med Chem, 52, 2109, 10.1021/jm900003c

Yamashita, 2009, New procedure for the synthesis of 2-alkylbenzimidazoles, Synth Commun, 39, 2982, 10.1080/00397910902730838